Impact of non-alcoholic hepatic steatosis on prognosis and clinical outcomes in gastric cancer patients undergoing laparoscopic distal gastrectomy

Table 1 Baseline characteristics before and after propensity score-matching, n (%)

Variables	Before PSM				After PSM
	NAFLD (n = 52)	Controls (n = 1070)	P value	SMD	NAFLD (n = 52)	Controls (n = 208)	P value	SMD
Age (years)	59.9 (13.9)	60.2 (11.1)	0.828	0.027	59.9 (13.9)	59.4 (11.0)	0.784	0.039
≤ 60	30 (57.7)	518 (48.4)			30 (57.7)	111 (53.4)
> 60	22 (42.3)	552 (51.6)			22 (42.3)	97 (46.6)
Gender			0.444	0.128			0.724	0.079
Male	31 (59.6)	704 (65.8)			31 (59.6)	132 (63.5)
Female	21 (40.4)	366 (34.2)			21 (40.4)	76 (36.5)
BMI	26.6 (3.0)	23.5 (3.1)	< 0.001a	1.046	26.6 (3.0)	23.9 (3.1)	< 0.001a	0.896
≤ 28	37	987			37	190
> 28	15	83			15	18
Preoperative CEA (ng/mL)	2.8 (4.0)	3.7 (9.8)	0.484	0.128	2.8 (4.0)	2.8 (4.3)	0.996	0.001
≤ 5	46 (88.5)	952 (89.0)			46 (88.5)	190 (91.3)
> 5	6 (11.5)	118 (11.0)			6 (11.5)	18 (8.7)
Preoperative CA724 (µg/L)	3.4 (4.0)	5.7 (19.2)	0.405	0.165	3.4 (4.0)	4.0 (8.5)	0.619	0.094
≤ 6.7	41 (78.8)	881 (82.3)			41 (78.8)	172 (82.7)
> 6.7	8 (15.4)	135 (12.6)			8 (15.4)	21 (10.1)
Preoperative CA199 (U/mL)	17.0 (29.2)	24.3 (88.7)	0.554	0.111	17.0 (29.2)	18.7 (74.6)	0.866	0.032
≤ 37	49 (94.2)	993 (92.8)			49 (94.2)	201 (96.6)
> 37	3 (5.8)	77 (7.2)			3 (5.8)	7 (3.4)

^aP < 0.05, statistically significant.

NAFLD: Non-alcoholic fatty liver disease; BMI: Body mass index; PSM: Propensity score-matching; SMD: standardized mean difference.